Novartis News

On Monday, February 13, Seattle Genetics will release its fourth quarter and year end results, and investors will get the first full-quarter sales data for Adcetris , the company's first marketed drug which was approved on August 19, 2011.

When you ask around the drug industry who the best leader of the last two decades was, Daniel Vasella's name always comes up.

This is the third in a series of articles highlighting dividend companies that have large and durable economic advantages, or "moats", that protect their business operations and allow years or decades of strong profitability.

Perhaps it is true that any press is good press. No one likes bad press, especially when others in the same field are receiving positive press.

Merck announces that top-line results of a study on Vorapaxar show that the drug significantly reduced the risk of cardiovascular events.

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules.

Novartis was downgraded by equities research analysts at Bank of America to an "underperform" rating in a research note issued to investors on Monday.

No longer. Last week, I chaired a panel of business leaders on the sidelines of the World Economic Forum in Davos .

NOVN.VX ) investors to vote against re-electing board members who were among those deciding on the pay awarded to the Swiss drugmaker's chairman, Daniel Vasella.

Shareholder group Ethos said Novartis investors should vote against re-electing board members in charge of allotting bonus pay to the Swiss drugmaker's chairman, Daniel Vasella.

Dendreon Corporation A names board member John Johnson as its president and Chief Executive Officer, beginning June 30.

Here is a current dividend list of stocks with interesting performance and valuation figures.

We are maintaining our Neutral stance on Endo Pharmaceuticals with a target price of $39.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and offers more than 175 products in the areas of pain management, urology and oncology.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Novartis is currently trading at $54.41, which is pretty close to the stock's 52-week low price of $51.60. The pharmaceutical company lost 15% of its market value since May, however year to year it's only down by 3%. This is because the company had a major rally before experiencing its plunge.

New five-year commitment includes donation of treatments worth an estimated USD 22.5 million and is expected to reach an estimated 850,000 patients The company has a long history in fighting leprosy, donating medicines and developing programs to support patients, valued at more than USD 100 million since 1986 Novartis is a part of an international ... (more)

Diversified healthcare giant Novartis reported impressive 2011 results in January 2012.

GenVec, Inc. , a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, today announced that it has extended its Research Collaboration and License Agreement with Novartis .

Abbott Laboratories A reported its results for the fourth quarter.A Net income for Abbott Laboratories rose to $1.62 billion vs.

Unity Management Group, Inc. is pleased to announce its wholly owned subsidiary Metropolitan Computing Corporation is opening 2012 with a great head start.